NEXTLEAP Cold Sore Care

A new breakthrough treatment approach for cold sores-Return to Normal in 1-2 Days!

Claim My Business
Security Type
Convertible Note
Healthcare & Medical, Consumer Goods & Products, Retail, Health & Fitness, Fashion & Accessories, Other
Min Investment
Dallas, TX
Expected Close Date
April 29, 2024
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Key Deal Facts

The cold sore market is very large but remains underserved.
Our novel and IP protected (via license) product provides new and improved results to customers.
Established with the leading online marketplaces and poised for rapid growth with added resources.
Continuous improvement in online marketing tools including addition of social media influencers
Monthly sales growth of 300% over the last year and accelerating
Hitting sales targets with repeat and new customers as expected

Management Team / Advisory Board Bios

Frank Murdock PrincipalLed worldwide neurosurgical business within Pfizer, Paul StewartPrincipalLed worldwide craniofacial business within Pfizer
Amount Raised : $106,800
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

A convertible security is a security that can be converted into another security, typically equity in the next round of financing.

Research Reports

No reports have been submitted

Become a Reporter